Catalog No.
PHE26003
Species reactivity
Human
Host species
Mouse
Isotype
IgG
Clonality
Polyclonal
Immunogen
Romiplostim
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Thrombopoietin, C-mpl ligand, ML, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, MGDF, Myeloproliferative leukemia virus oncogene ligand, THPO, MGDF
Purification
Purified by antigen affinity column.
Accession
P40225
Applications
ELISA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Romiplate, Romiplostim, Nplate
The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering., PMID:40384450
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia., PMID:39852180
The Establishment of a Novel Murine Model of Immune Thrombocytopenia in Pregnancy and the Impacts of Thrombopoietin Receptor Agonist on Platelet Production., PMID:39539867
[Pharmacotherapy for aplastic anemia]., PMID:39505555
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies., PMID:39348667
Peptibodies: Bridging the gap between peptides and antibodies., PMID:39142490
Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report., PMID:39130867
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management., PMID:39105265
Acute Renal Thrombotic Microangiopathy Caused by Eltrombopag and Romiplostim in a Patient with Myelodysplastic Syndromes (MDS) and Underlying Antiphospholipid Syndrome., PMID:38984183
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment., PMID:38942688
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice., PMID:38843478
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data., PMID:38465414
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy., PMID:38425280
Severe thrombocytopenia associated to bevacizumab in a patient with scleroderma, gastrointestinal angiodysplasias and refractory gastrointestinal bleeding., PMID:38358904
Concomitant presentation of thrombotic thrombocytopenic purpura, immune thrombocytopenia, and autoimmune hemolytic anemia in a patient with newly diagnosed systemic lupus erythematosus., PMID:38170038
Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity., PMID:38168134
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment., PMID:37985171
Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings - Connecticut, July 2022., PMID:37733629
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism., PMID:37594915
Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment., PMID:37395226
Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates., PMID:37335880
Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence., PMID:37300567
Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience., PMID:37247631
Accelerated death of megakaryocytes from Wiskott-Aldrich syndrome patients., PMID:37221654
Severe immune thrombocytopenia in two patients with systemic sclerosis., PMID:36933783
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model., PMID:36928007
Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database., PMID:36803342
[Hematopoietic recovery by ASXL1-mutated clones after immune suppressive therapy in a patient with severe aplastic anemia]., PMID:36775307
Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice., PMID:36269841
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study., PMID:36257098
Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim., PMID:36253251
Chemically modified in-vitro-transcribed mRNA encoding thrombopoietin stimulates thrombopoiesis in mice., PMID:36090760
Paraneoplastic syndromes: A focus on pathophysiology and supportive care., PMID:35916756
Pembrolizumab-Induced Acquired Amegakaryocytic Thrombocytopenia and Successful Combination Treatment With Eltrombopag, Romiplostim and Cyclosporine: A Brief Communication., PMID:35791464
Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome., PMID:35561254
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia., PMID:35413092
Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution., PMID:35306963
Drug-induced antiphospholipid syndrome: Analysis of the WHO international database., PMID:35114404
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials., PMID:34962697
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry., PMID:34638135
Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany., PMID:34547980
COVID-19 induced immune thrombocytopenic purpura: case report., PMID:34386543
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment., PMID:33827138
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review., PMID:33796239
Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim., PMID:33768076
UK second-line paediatric primary ITP therapy analysis., PMID:33597180
Persistent Immune Thrombocytopenia Resistant to Immunosuppressive Therapy: What Is the Way Forward?, PMID:33527058
Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia., PMID:33491968
Therapy for lower-risk MDS., PMID:33275714
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia., PMID:33249935
For research use only. Not for human or drug use.
